Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971413 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL5561305 | 0.81 | NPY5R (0.43) | FFAR1LMNAL3MBTL1FFAR4 | |
| SCHEMBL4972539 | 0.80 | LPAR1 (0.44) | FFAR1FFAR4MAPK1HSD17B2 | |
| SCHEMBL4969555 | 0.79 | PTPN11 (0.42) | FFAR1 | |
| SCHEMBL4969521 | 0.79 | PTGER4 (0.47) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL4969923 | 0.77 | HSD17B2 (0.48) | FFAR1LMNAFFAR4AKR1B1KMT2A | |
| SCHEMBL4971469 | 0.76 | AOC3 (0.44) | FFAR1FFAR4 | |
| SCHEMBL5561298 | 0.76 | ITGB3 (0.52) | KMT2A | |
| SCHEMBL4971665 | 0.75 | HSD17B2 (0.48) | FFAR1LMNAKMT2AHSD17B2 | |
| SCHEMBL4971902 | 0.75 | AOC3 (0.60) | FFAR1FFAR4AKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| EP-1781274-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018325-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | claimed |
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | FFAR1 13/4885LMNA 2446/4885L3MBTL1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.